Fenofibrate

Fenofibrate
Clinical data
Trade namesFenoglide, Lipofen, others
AHFS/Drugs.comMonograph
MedlinePlusa601052
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • UK: POM (Prescription only)[2]
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding99%
Metabolismglucuronidation
Elimination half-life20 h
Excretionurine (60%), feces (25%)
Identifiers
  • propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.051.234 Edit this at Wikidata
Chemical and physical data
FormulaC20H21ClO4
Molar mass360.83 g·mol−1
3D model (JSmol)
Melting point80 to 81 °C (176 to 178 °F)
  • O=C(c1ccc(Cl)cc1)c2ccc(OC(C(=O)OC(C)C)(C)C)cc2
  • InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3 checkY
  • Key:YMTINGFKWWXKFG-UHFFFAOYSA-N checkY
  (verify)

Fenofibrate (sold under the brand name Tricor among others, is an oral medication of the fibrate class used to treat abnormal blood lipid levels.[3] It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.[3][4][5] Its use is recommended together with dietary changes.[3]

Common side effects include liver problems, breathing problems, abdominal pain, muscle problems, and nausea.[3] Serious side effects may include toxic epidermal necrolysis, rhabdomyolysis, gallstones, and pancreatitis.[3] Use during pregnancy and breastfeeding is not recommended.[6][7] It works by multiple mechanisms.[3]

It was patented in 1969, and came into medical use in 1975.[8] It is available as a generic medication.[6] In 2022, it was the 88th most commonly prescribed medication in the United States, with more than 7 million prescriptions.[9][10]

  1. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  2. ^ "Fenofibrate 267mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 12 February 2020. Retrieved 13 April 2020.
  3. ^ a b c d e f "Fenofibric Acid/Fenofibrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  4. ^ Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al. (April 2010). "Effects of combination lipid therapy in type 2 diabetes mellitus". The New England Journal of Medicine. 362 (17): 1563–1574. doi:10.1056/NEJMoa1001282. PMC 2879499. PMID 20228404.{{cite journal}}: CS1 maint: overridden setting (link)
  5. ^ Kim NH, Han KH, Choi J, Lee J, Kim SG (September 2019). "Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study". BMJ. 366: l5125. doi:10.1136/bmj.l5125. PMC 6763755. PMID 31562117. S2CID 203580658.
  6. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 198. ISBN 9780857113382.
  7. ^ "Fenofibrate Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
  8. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.
  9. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  10. ^ "Fenofibrate Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.